“We look forward to presenting preclinical data at ASGCT that underscore the potential of our in vivo HSC engineering platform to address complex genetic disorders and cancer,” said Robert Peters, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback